aspirin and Renal Insufficiency, Chronic studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)

Research Excerpts

Excerpt	Relevance	Reference
"Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin."	9.51	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022)
"Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0."	9.22	Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016)
" Among stage III CKD patients, apixaban significantly reduced stroke relative to aspirin without a significant increase in major hemorrhage."	9.16	Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012)
"The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD)."	8.02	Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study : This is the study for kidney and pregnancy... ( Chen, Q; Chen, S; He, Y; Wang, M; Yang, H; Zhao, M, 2021)
" Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups."	7.96	Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020)
"There was no significant benefit in preventing ischemic stroke in the patients with advanced CKD who received aspirin therapy."	7.85	Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017)
" The adequate hydration group received continuous intravenous infusion of isosorbide dinitrate combined with intravenous infusion of isotonic saline at a rate of 1."	6.90	Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure. ( Chen, Y; Dong, W; Guo, J; Liu, CF; Qian, G; Wang, J, 2019)
"Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin."	5.51	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022)
" Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD."	5.51	Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov ( Dumbleton, J; Fitzmaurice, D; Fraser, SD; Fuat, A; Gallagher, H; Griffith, KE; Hawkey, CJ; Henderson, RA; Lord, J; Lown, M; Maishman, T; Moore, MV; Roderick, PJ; Stevens, P; Stevenson, D; Taal, MW; Whitehead, A, 2022)
"5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding."	5.30	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. ( Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S, 2019)
"Aspirin cannot be routinely recommended for the primary prevention of CVD in individuals with CKD as there is no evidence for its benefit but there is an increased risk of bleeding."	5.22	Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. ( Ashton, L; Brunskill, NJ; Burton, JO; Gray, LJ; Major, RW; Pallikadavath, S, 2022)
"Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0."	5.22	Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016)
" During the randomized phase, there were small but significant differences between the groups in BP, proteinuria, LDL cholesterol, and use of aspirin, statins, active vitamin D, and antihypertensive medications, in favor of the intervention group."	5.19	Nurse practitioner care improves renal outcome in patients with CKD. ( Blankestijn, PJ; Bots, ML; Kaasjager, KA; Ligtenberg, G; Peeters, MJ; Sijpkens, YW; Sluiter, HE; Ten Dam, MA; van Buren, M; van de Ven, PJ; van den Brand, JA; van Zuilen, AD; Vervoort, G; Vleming, LJ; Wetzels, JF, 2014)
" Among stage III CKD patients, apixaban significantly reduced stroke relative to aspirin without a significant increase in major hemorrhage."	5.16	Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012)
"Our review indicated that aspirin use in CKD patients had no prevention effect on cardiovascular events and no statistically significant reduction in risk of cardiovascular or all-cause mortality, with a significant increased risk of minor bleeding and renal events."	5.05	Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. ( He, Y; Li, M; Lu, H; Qu, B; Wu, H; Wu, L, 2020)
" Dabigatran (150 mg twice daily) and apixaban reduced risk of stroke or systemic embolism significantly more than warfarin for moderate CKD patients (HR 0."	5.01	A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. ( Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S, 2019)
" Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI)."	4.90	p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. ( Alexopoulos, D, 2014)
"Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily."	4.31	Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. ( Anderson, RD; Benziger, CP; Bradley, SM; DeWalt, DA; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kim, H; Knowlton, KU; Mehta, H; Muñoz, D; Pepine, CJ; Polonsky, TS; Rothman, RL; Stebbins, A; Whittle, J; Wruck, LM; Zhou, L, 2023)
"Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score."	4.12	Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022)
"The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD)."	4.02	Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study : This is the study for kidney and pregnancy... ( Chen, Q; Chen, S; He, Y; Wang, M; Yang, H; Zhao, M, 2021)
" Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups."	3.96	Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020)
" Cox proportional hazard regression models were developed to evaluate the predictors of LGIB with adjustments for age, gender, comorbidities including coronary artery disease, ischaemic stroke, diabetes, hypertension, chronic kidney disease, liver cirrhosis, chronic obstructive pulmonary disease, dyslipidemia, uncomplicated peptic ulcer disease, history of peptic ulcer bleeding, and concomitant use of clopidogrel, ticlopidine, warfarin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, steroids, proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), nitrates, alendronate, selective serotonin reuptake inhibitors (SSRIs) and calcium channel blockers."	3.85	The risk of lower gastrointestinal bleeding in low-dose aspirin users. ( Chen, WC; Chuah, SK; Hsu, PI; Huang, YT; Lin, KH; Sun, WC; Tsai, TJ; Wu, DC, 2017)
"Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)."	3.85	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017)
"There was no significant benefit in preventing ischemic stroke in the patients with advanced CKD who received aspirin therapy."	3.85	Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017)
"Little is known about the ischaemic stroke risk and benefit of warfarin therapy for stroke prevention in chronic kidney disease (CKD) patients on peritoneal dialysis (PD) with concomitant atrial fibrillation (AF)."	3.83	Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. ( Chan, PH; Chan, TM; Hai, J; Huang, D; Lip, GY; Lo, WK; Siu, CW; Tse, HF; Yip, PS, 2016)
" Of all patients, 3585 met the inclusion criteria and underwent the analysis to determine the association of preoperative aspirin with incidence of acute kidney injury (AKI) and death based on estimated glomerular filtration rate (eGFR)."	3.81	Evidence for preoperative aspirin improving major outcomes in patients with chronic kidney disease undergoing cardiac surgery: a cohort study. ( Diehl, J; Goldhammer, J; He, J; Li, Z; Liu, H; Sun, J; Sun, W; Tao, L; Yao, L; Young, N, 2015)
"This study assessed the risk associated with CKD in individual CHA₂DS₂-VASc (Congestive heart failure; Hypertension; Age ≥75 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism; Vascular disease; Age 65 to 74 years; Sex category) strata and the net clinical benefit of warfarin in patients with AF and CKD in a nationwide cohort."	3.80	Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. ( Bonde, AN; Gislason, GH; Hansen, ML; Hansen, PR; Hommel, K; Kamper, AL; Lamberts, M; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2014)
"Aspirin users were at significantly lower risk of all-cause mortality compared to nonusers (HR = 0."	3.01	Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. ( Bond, M; Conant, A; Desai, N; Rahman, M; Wilson, B, 2021)
" Veverimer is not systemically absorbed, so potential drug-drug interactions (DDIs) are limited to effects on the absorption of other oral drugs through binding to veverimer in the gastrointestinal tract or increases in gastric pH caused by veverimer binding to hydrochloric acid."	3.01	Assessment of the Potential for Veverimer Drug-Drug Interactions. ( Biyani, K; Guttendorf, R; Klaerner, G; Lee, A; Li, E; Mathur, V; Parsell, D; Shao, J; Stasiv, Y; Tabakman, S; Tsao, L; Wu, YS, 2021)
" The adequate hydration group received continuous intravenous infusion of isosorbide dinitrate combined with intravenous infusion of isotonic saline at a rate of 1."	2.90	Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure. ( Chen, Y; Dong, W; Guo, J; Liu, CF; Qian, G; Wang, J, 2019)
"Aspirin treatment decreased renal disease progression in a model adjusted for age, baseline kidney function, and diabetes mellitus (HR, 0."	2.87	Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). ( Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018)
"Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality."	2.61	Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019)
" Avoidance of nephrotoxic and teratogenic medications is necessary, and renal dosing of commonly used medications must also be considered."	2.61	Chronic Kidney Disease and Pregnancy. ( Hladunewich, MA; Hui, D, 2019)
"Aspirin is likely to increase the risk of major bleeding events."	2.53	Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. ( Brunskill, NJ; Dawson, S; Gray, LJ; Major, RW; Oozeerally, I; Riddleston, H, 2016)
"Different dosage forms of ASA are characterized with similar efficacy in prevention of cardiovascular events and effects on the risk of bleeding."	1.51	[Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease]. ( Erofeeva, SG; Karpukhina, EV; Nekrasov, AA; Timoshchenko, ES, 2019)
" The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs."	1.43	Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. ( Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016)
"Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding."	1.38	Stroke and bleeding in atrial fibrillation with chronic kidney disease. ( Gislason, GH; Hommel, K; Kamper, AL; Køber, L; Lane, DA; Lindhardsen, J; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2012)

Research

Studies (93)

Authors

Clinical Trials (17)

Trial Overview

Trial Outcomes

Cumulative Event Rate of Death From Any Cause or Myocardial Infarction

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (1.08)	29.6817
2010's	59 (63.44)	24.3611
2020's	33 (35.48)	2.80

Authors	Studies
Ernst, ME	4
Fravel, MA	1
Webb, KL	1
Wetmore, JB	3
Wolfe, R	4
Chowdhury, E	1
Reid, CM	3
Woods, RL	4
Beilin, L	1
Margolis, KL	1
Murray, AM	3
Polkinghorne, KR	6
Auer, J	1
Lamm, G	1
Dai, L	1
Xu, J	1
Yan, H	1
Chen, Z	1
Pan, Y	2
Meng, X	2
Li, H	2
Wang, Y	4
Dehghani, P	1
Cao, D	1
Baber, U	2
Nicolas, J	1
Sartori, S	1
Pivato, CA	1
Zhang, Z	1
Dangas, G	1
Angiolillo, DJ	1
Briguori, C	2
Cohen, DJ	1
Collier, T	1
Dudek, D	1
Gibson, M	1
Gil, R	1
Huber, K	1
Kaul, U	2
Kornowski, R	1
Krucoff, MW	1
Kunadian, V	1
Mehta, S	1
Moliterno, DJ	1
Ohman, EM	1
Escaned, J	1
Sardella, G	1
Sharma, SK	1
Shlofmitz, R	1
Weisz, G	2
Witzenbichler, B	2
Pocock, S	1
Mehran, R	2
Thao, LTP	1
Nelson, MR	2
Shah, RC	2
McNeil, JJ	3
Gallagher, H	3
Dumbleton, J	1
Maishman, T	1
Whitehead, A	1
Moore, MV	1
Fuat, A	2
Fitzmaurice, D	1
Henderson, RA	1
Lord, J	1
Griffith, KE	1
Stevens, P	1
Taal, MW	1
Stevenson, D	1
Fraser, SD	1
Lown, M	2
Hawkey, CJ	1
Roderick, PJ	1
Mathew, RO	2
Maron, DJ	1
Anthopolos, R	1
Fleg, JL	1
O'Brien, SM	1
Rockhold, FW	1
Roik, MF	1
Mazurek, T	1
Demkow, M	1
Malecki, R	1
Ye, Z	1
Miglinas, M	1
Stone, GW	2
Wald, R	1
Charytan, DM	1
Sidhu, MS	2
Hochman, JS	1
Bangalore, S	1
Walker, RG	1
Bongetti, E	1
Ryan, J	1
Espinoza, S	1
Murray, A	1
Haim-Pinhas, H	1
Yoskovitz, G	1
Lishner, M	1
Pereg, D	1
Kitay-Cohen, Y	1
Topaz, G	1
Sela, Y	1
Wand, O	1
Rozenberg, I	1
Benchetrit, S	1
Cohen-Hagai, K	1
Carlin, S	1
de Vries, TAC	1
Budaj, A	1
Eikelboom, J	1
Roshanov, PS	1
Garg, AX	2
Gupta, K	1
Mehta, H	1
Kim, H	1
Stebbins, A	1
Wruck, LM	1
Muñoz, D	1
Effron, MB	1
Anderson, RD	1
Pepine, CJ	1
Jain, SK	1
Girotra, S	1
DeWalt, DA	1
Whittle, J	1
Benziger, CP	1
Farrehi, P	1
Zhou, L	1
Knowlton, KU	1
Polonsky, TS	1
Bradley, SM	1
Harrington, RA	1
Rothman, RL	1
Jones, WS	1
Hernandez, AF	1
Sepanlou, SG	1
Mann, JFE	1
Joseph, P	1
Pais, P	1
Gao, P	2
Sharafkhah, M	1
Roshandel, G	1
Yusuf, S	3
Malekzadeh, R	1
Festa, MC	1
Rasasingam, S	1
Sharma, A	1
Mavrakanas, TA	1
Rubin, GA	1
Kirtane, AJ	1
Chen, S	3
Redfors, B	1
Zhang, Y	1
Stuckey, TD	1
Rinaldi, MJ	1
Neumann, FJ	1
Metzger, DC	1
Henry, TD	1
Cox, DA	1
Duffy, PL	1
Brodie, BR	1
Mazzaferri, EL	1
Ali, ZA	1
Ben-Yehuda, O	1
Roderick, P	2
Qu, B	1
He, Y	2
Wu, L	1
Lu, H	1
Wu, H	1
Li, M	1
Lopau, K	1
Wanner, C	1
Shoji, S	1
Sawano, M	1
Sandhu, AT	1
Heidenreich, PA	1
Shiraishi, Y	1
Ikemura, N	1
Ueno, K	2
Suzuki, M	1
Numasawa, Y	1
Fukuda, K	1
Kohsaka, S	1
Clemens, KK	1
Woodward, M	1
Neal, B	1
Zinman, B	1
Ilardi, F	1
Gargiulo, G	1
Paolillo, R	1
Ferrone, M	1
Cimino, S	1
Giugliano, G	1
Schiattarella, GG	1
Verde, N	1
Stabile, E	1
Perrino, C	1
Cirillo, P	1
Coscioni, E	1
Morisco, C	1
Esposito, G	1
Mitsuboshi, S	1
Yamada, H	1
Yamazaki, S	1
Kobayashi, M	2
Nagai, K	1
Kataruka, A	1
Mahtta, D	1
Akeroyd, JM	1
Hira, RS	1
Kazi, DS	1
Spertus, JA	2
Bhatt, DL	2
Petersen, LA	1
Ballantyne, CM	1
Virani, SS	1
Gerstman, BB	1
Walker, R	1
Lockery, JE	1
Tonkin, AM	1
Abhayaratna, WP	1
Gibbs, P	1
Wood, EM	1
Mahady, SE	1
Williamson, JD	1
Donnan, GA	1
Cloud, GC	1
Desai, N	1
Wilson, B	1
Bond, M	1
Conant, A	1
Rahman, M	1
Major, RW	3
Burton, JO	2
Oh, YJ	1
Kim, AJ	2
Ro, H	2
Chang, JH	2
Lee, HH	2
Chung, W	2
Hyun, YY	1
Lee, J	1
Kim, YH	1
Han, SH	1
Chae, DW	1
Ahn, C	1
Oh, KH	1
Jung, JY	2
Sandner, SE	1
Schunkert, H	1
Kastrati, A	1
Milojevic, M	1
Böning, A	1
Zimpfer, D	1
Zellmer, S	1
Wiedemann, D	1
Laufer, G	1
von Scheidt, M	1
Wang, M	1
Zhao, M	1
Yang, H	1
Chen, Q	1
Shiroma, S	1
Hatta, W	1
Tsuji, Y	1
Yoshio, T	1
Yabuuchi, Y	1
Hoteya, S	1
Tsuji, S	1
Nagami, Y	1
Hikichi, T	1
Morita, Y	1
Sumiyoshi, T	1
Iguchi, M	1
Tomida, H	1
Inoue, T	1
Mikami, T	1
Hasatani, K	1
Nishikawa, J	1
Matsumura, T	2
Nebiki, H	1
Nakamatsu, D	1
Ohnita, K	1
Suzuki, H	1
Ueyama, H	1
Hayashi, Y	1
Sugimoto, M	1
Yamaguchi, S	1
Michida, T	1
Yada, T	1
Asahina, Y	1
Narasaka, T	1
Kuribayashi, S	1
Kiyotoki, S	1
Mabe, K	1
Fujishiro, M	1
Masamune, A	1
Fujisaki, J	1
Parsell, D	1
Shao, J	1
Guttendorf, R	1
Mathur, V	1
Li, E	1
Wu, YS	1
Tsao, L	1
Tabakman, S	1
Stasiv, Y	1
Lee, A	1
Biyani, K	1
Klaerner, G	1
Trejo-Velasco, B	1
Tello-Montoliu, A	1
Cruz-González, I	1
Moreno, R	1
Baz-Alonso, JA	1
Salvadores, PJ	1
Romaguera, R	1
Molina-Navarro, E	1
Paredes-Galán, E	1
Fernández-Barbeira, S	1
Ortiz-Saez, A	1
Bastos-Fernandez, G	1
De Miguel-Castro, A	1
Figueiras-Guzman, A	1
Iñiguez-Romo, A	1
Jimenez-Diaz, VA	1
Pallikadavath, S	1
Ashton, L	1
Brunskill, NJ	2
Gray, LJ	2
Chen, WC	1
Lin, KH	1
Huang, YT	1
Tsai, TJ	1
Sun, WC	2
Chuah, SK	2
Wu, DC	2
Hsu, PI	2
Violi, F	1
Targher, G	1
Vestri, A	1
Carnevale, R	1
Averna, M	1
Farcomeni, A	1
Lenzi, A	1
Angelico, F	1
Cipollone, F	1
Pastori, D	1
Goicoechea, M	2
Sanchez-Niño, MD	1
Ortiz, A	2
García de Vinuesa, S	1
Quiroga, B	2
Bernis, C	2
Morales, E	2
Fernández-Juarez, G	2
de Sequera, P	2
Verdalles, U	2
Verde, E	2
Luño, J	2
Kumar, S	1
de Lusignan, S	1
McGovern, A	1
Correa, A	1
Hriskova, M	1
Gatenby, P	1
Jones, S	1
Goldsmith, D	1
Camm, AJ	1
Gregg, LP	1
Hedayati, SS	2
Feldberg, J	1
Patel, P	1
Farrell, A	1
Sivarajahkumar, S	1
Cameron, K	1
Ma, J	1
Battistella, M	1
Locham, S	1
Beaulieu, RJ	1
Dakour-Aridi, H	1
Nejim, B	1
Malas, MB	1
Gosmanova, EO	1
de Vinuesa, SG	1
Delgado, R	1
Torres, A	1
Arroyo, D	1
Abad, S	1
Qian, G	1
Liu, CF	1
Guo, J	1
Dong, W	1
Wang, J	2
Chen, Y	1
So, S	1
Ahn, JY	1
Kim, N	1
Na, HK	1
Jung, KW	1
Lee, JH	1
Kim, DH	1
Choi, KD	1
Song, HJ	1
Lee, GH	1
Jung, HY	1
Horyniecki, M	1
Łącka-Gaździk, B	1
Niewiadomska, E	1
Mazur, B	1
Śnit, M	1
Łabuz-Roszak, B	1
Nekrasov, AA	1
Timoshchenko, ES	1
Erofeeva, SG	1
Karpukhina, EV	1
Reddy, S	1
Jim, B	1
Fox, KAA	1
Eikelboom, JW	2
Shestakovska, O	1
Connolly, SJ	2
Metsarinne, KP	1
Hui, D	1
Hladunewich, MA	1
Kim, SJ	1
Bang, OY	1
Lin, CC	1
Hu, HY	1
Luo, JC	1
Peng, YL	1
Hou, MC	1
Lin, HC	1
Lee, FY	1
Aksu, HU	1
Oner, E	1
Erturk, M	1
Aksu, H	1
Isıksacan, N	1
Ozalp, B	1
Akture, G	1
Akbay, E	1
Ozer, L	1
Erol, MK	1
Peeters, MJ	1
van Zuilen, AD	1
van den Brand, JA	1
Bots, ML	1
van Buren, M	1
Ten Dam, MA	1
Kaasjager, KA	1
Ligtenberg, G	1
Sijpkens, YW	1
Sluiter, HE	1
van de Ven, PJ	1
Vervoort, G	1
Vleming, LJ	1
Blankestijn, PJ	1
Wetzels, JF	1
Guo, X	1
Ma, H	1
Hao, X	1
Li, J	1
Alexopoulos, D	1
Kurz, A	1
Sessler, DI	1
Cuerden, M	1
Robinson, A	1
Mrkobrada, M	1
Parikh, C	1
Mizera, R	1
Jones, PM	1
Tiboni, M	1
Rodriguez, RG	1
Popova, E	1
Rojas Gomez, MF	1
Meyhoff, CS	1
Vanhelder, T	1
Chan, MT	1
Torres, D	1
Parlow, J	1
de Nadal Clanchet, M	1
Amir, M	1
Bidgoli, SJ	1
Pasin, L	1
Martinsen, K	1
Malaga, G	1
Myles, P	1
Acedillo, R	1
Roshanov, P	1
Walsh, M	1
Dresser, G	1
Kumar, P	1
Fleischmann, E	1
Villar, JC	1
Painter, T	1
Biccard, B	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Aspirin in Reducing Events in the Elderly[NCT01038583]		19,114 participants (Actual)	Observational	2010-01-31	Active, not recruiting
Aspirin to Target Arterial Events in Chronic Kidney Disease[NCT03796156]	Phase 3	25,210 participants (Anticipated)	Interventional	2019-02-25	Recruiting
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial[NCT01985360]	Phase 4	777 participants (Actual)	Interventional	2014-01-31	Completed
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial[NCT05283356]	Phase 4	1,206 participants (Anticipated)	Interventional	2022-01-21	Recruiting
Effect of Aspirin on Renal Disease Progression in Patients With Type 2 Diabetes: a Multicentre Double-blind, Placebo-controlled, Randomised Trial. The LEDA (renaL disEase Progression by Aspirin in Diabetic pAtients) Study.[NCT02895113]	Phase 3	418 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)[NCT01709994]	Phase 3	97 participants (Anticipated)	Interventional	2010-05-31	Recruiting
Chinese People's Liberation Army General Hospital[NCT02718521]		400 participants (Anticipated)	Interventional	2016-03-31	Active, not recruiting
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event[NCT01082874]	Phase 3	10,010 participants (Actual)	Interventional	2010-07-31	Completed
Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709]	Phase 4	7 participants (Actual)	Interventional	2016-04-30	Completed
The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236]		150 participants (Actual)	Interventional	2016-07-31	Completed
Effects of Synbiotics Supplementation on the Concentration of the Uremic Toxin Indoxyl Sulfate, Symptoms of Constipation, and Constipation-related Quality of Life in End-stage Renal Disease Patients Undergoing Hemodialysis[NCT04527640]		60 participants (Anticipated)	Interventional	2020-09-15	Not yet recruiting
Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794]		300 participants (Actual)	Observational [Patient Registry]	2018-03-14	Completed
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643]	Phase 3	220 participants (Actual)	Interventional	2009-04-30	Completed
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin[NCT01768637]	Phase 1	48 participants (Actual)	Interventional	2013-01-31	Completed
Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589]	Phase 3	5,100 participants (Actual)	Interventional	2009-12-31	Completed
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407]	Phase 4	154 participants (Actual)	Interventional	2016-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

This measure represents the estimated cumulative probability of experiencing Death from any cause or Myocardial Infarction within the indicated timeframe in each treatment group. The interpretation of the measure is similar to Kaplan-Meier event rates. Estimates are expressed as percentages ranging from 0% (endpoint is certain not to occur) to 100% (endpoint is certain to occur). (NCT01985360)
Timeframe: 3 years

Incidence of Death From Any Cause or Myocardial Infarction

All-cause Mortality

Intervention	cumulative event rate - % (Number)
Invasive Strategy	36.4
Conservative Strategy	36.7

Intervention	Participants (Count of Participants)
Invasive Strategy	123
Conservative Strategy	129

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

All-cause Mortality in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	313
Rivaroxaban 5mg + Aspirin Placebo	366
Rivaroxaban Placebo + Aspirin 100mg	378

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	282

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	389
Rivaroxaban 5mg + Aspirin Placebo	453
Rivaroxaban Placebo + Aspirin 100mg	516

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	329
Rivaroxaban 5mg + Aspirin Placebo	397
Rivaroxaban Placebo + Aspirin 100mg	450

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	379
Rivaroxaban 5mg + Aspirin Placebo	448
Rivaroxaban Placebo + Aspirin 100mg	496

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	353

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	288
Rivaroxaban 5mg + Aspirin Placebo	255
Rivaroxaban Placebo + Aspirin 100mg	170

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

Composite of All-cause Mortality and Nonfatal MI

Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	138

Intervention	participants (Number)
Active Clonidine and Active ASA	173
Active Clonidine and Placebo ASA	194
Placebo Clonidine and Active ASA	178
Placebo Clonidine and Placebo ASA	161

Citrated whole blood was used to measure platelet aggregation induced by agonist (arachidonic acid at 5 mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks

Whole Blood Platelet Aggregation to 2 µg/mL Collagen

Intervention	ohms (Median)
	Baseline	visit 2
Chronic Kidney Disease	21.0	0
Normal Controls	18.0	0

Citrated whole blood was used to measure platelet aggregation induced by agonist (collagen at 2mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks

Whole Blood Platelet Aggregation to 20 µg/mL Adenosine Diphosphate

Intervention	ohms (Median)
	Baseline	visit 2
Chronic Kidney Disease	28.5	19.5
Normal Controls	25.0	19.0

Citrated whole blood was used to measure platelet aggregation induced by agonist (adenosine diphosphate at 20mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) and on aspirin (visit 2) was compared between groups with post treatment values (visit 3) after 2 weeks of aspirin and clopidogrel treatment (NCT01768637)
Timeframe: 4 weeks

Apixaban Plasma Concentration, Cmax

Intervention	ohms (Mean)
	Baseline	visit 2	visit 3
Chronic Kidney Disease	13.5	11.0	8.0
Normal Controls	9.0	10.0	3.0

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Apixaban Plasma Concentration, Cmin

Intervention	ng/mL (Geometric Mean)
Apixaban 2.5 mg	59.7
Apixaban 5 mg	97.9

Area Under the Plasma Apixaban Concentration Curve From 0 to 12 Hours After Dose (AUCO-12)

Intervention	ng/mL (Geometric Mean)
Apixaban 2.5 mg	28.2
Apixaban 5mg	49.7

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding

Intervention	ng*h/mL (Geometric Mean)
Apixaban 2.5 mg	507
Apixaban 5mg	868

"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Number of Participants Experiencing Mortality

Intervention	Participants (Count of Participants)
Apixaban	21
Warfarin	16

Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Number of Participants Experiencing Stroke

Intervention	Participants (Count of Participants)
Apixaban	21
Warfarin	13

"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Number of Participants Experiencing Stroke or Systemic Embolism

Intervention	Participants (Count of Participants)
Apixaban	2
Warfarin	2

Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Number of Participants Experiencing Stroke, Systemic Embolism, Major Bleeding or All-cause Mortality

Intervention	Participants (Count of Participants)
Apixaban	2
Warfarin	2

"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Number of Participants Experiencing Systemic Embolism

Intervention	Participants (Count of Participants)
Apixaban	27
Warfarin	29

"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Persistence of Therapy

Intervention	Participants (Count of Participants)
Apixaban	0
Warfarin	0

Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

Article	Year
Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis. Clinical journal of the American Society of Nephrology : CJASN, 2023, 11-01, Volume: 18, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial	2023
Early Discontinuation of Aspirin Among Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention with a Drug-Eluting Stent: A Meta-Analysis. Kidney360, 2023, 09-01, Volume: 4, Issue:9 Topics: Aspirin; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhib	2023
Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. International urology and nephrology, 2020, Volume: 52, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Renal Insuffi	2020
[Treatment of coronary artery disease in renal insufficiency]. Der Internist, 2020, Volume: 61, Issue:4 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Aspirin; Cardiovascular Diseases; Cor	2020
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. Diabetes care, 2020, Volume: 43, Issue:5 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis	2020
Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. European journal of preventive cardiology, 2022, 02-03, Volume: 28, Issue:17 Topics: Adult; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Renal Insufficiency	2022
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, Volume: 72, Issue:5 Topics: Age Factors; Aspirin; Cardiovascular Diseases; Comorbidity; Disease Management; Disease Progression;	2018
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 02-01, Volume: 34, Issue:2 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular	2019
Hypertension and Pregnancy: Management and Future Risks. Advances in chronic kidney disease, 2019, Volume: 26, Issue:2 Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human	2019
Chronic Kidney Disease and Pregnancy. Obstetrics and gynecology, 2019, Volume: 133, Issue:6 Topics: Aspirin; Female; Glomerular Filtration Rate; Humans; Hypertension, Pregnancy-Induced; Infant, Newbor	2019
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease. Contributions to nephrology, 2013, Volume: 179 Topics: Aspirin; Cerebrovascular Circulation; Cohort Studies; Endothelium, Vascular; Female; Hemorrhage; Hum	2013
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. Cardiology, 2014, Volume: 127, Issue:4 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Huma	2014
Cardiovascular disease and its relationship with chronic kidney disease. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:19 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Cardiovascular Diseases;	2014
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease. BMJ case reports, 2015, Oct-05, Volume: 2015 Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H	2015
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease. Circulation, 2016, Apr-12, Volume: 133, Issue:15 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C	2016
Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis, 2016, Volume: 251 Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as T	2016
Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nature clinical practice. Nephrology, 2009, Volume: 5, Issue:2 Topics: Animals; Aspirin; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Spir	2009
Coronary stent thrombosis in patients with chronic renal insufficiency. Angiology, 2010, Volume: 61, Issue:3 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma	2010

Article	Year
Long-Term Blood Pressure Variability and Kidney Function in Participants of the ASPREE Trial. American journal of hypertension, 2022, 02-01, Volume: 35, Issue:2 Topics: Aged; Aspirin; Australia; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hypertension;	2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-29, Volume: 8, Issue:7 Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe	2022
Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022, Volume: 80, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Renal Insuf	2022
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov Trials, 2022, Apr-21, Volume: 23, Issue:1 Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Multicenter S	2022
Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. Circulation. Cardiovascular quality and outcomes, 2022, Volume: 15, Issue:10 Topics: Aspirin; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarc	2022
TIPS to decide whether to prescribe aspirin for the primary prevention of cardiovascular events in chronic kidney disease. Kidney international, 2023, Volume: 103, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Renal	2023
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Budgets; Cardiovascular Diseases; Ci	2021
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney international, 2021, Volume: 99, Issue:2 Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Hemorrhage; Humans; Renal Insu	2021
Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. Journal of clinical hypertension (Greenwich, Conn.), 2021, Volume: 23, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency,	2021
Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. The Annals of thoracic surgery, 2022, Volume: 113, Issue:2 Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Meth	2022
Assessment of the Potential for Veverimer Drug-Drug Interactions. Drug metabolism and disposition: the biological fate of chemicals, 2021, Volume: 49, Issue:7 Topics: Absorption, Physicochemical; Acidosis; Administration, Oral; Adolescent; Adult; Aspirin; Cross-Over	2021
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of cardiovascular pharmacology, 2021, 09-01, Volume: 78, Issue:3 Topics: Aged; Aged, 80 and over; Anemia; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Comor	2021
Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American heart journal, 2017, Volume: 189 Topics: Aspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Re	2017
Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins, leukotrienes, and essential fatty acids, 2017, Volume: 125 Topics: Aged; Anti-Inflammatory Agents; Aspirin; Female; Glomerular Filtration Rate; Humans; Lipoxins; Male;	2017
Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:3 Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Female; Glomerul	2018
Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure. Clinical cardiology, 2019, Volume: 42, Issue:1 Topics: Acute Kidney Injury; Aged; Aspirin; China; Contrast Media; Coronary Angiography; Double-Blind Method	2019
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18 Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Comb	2019
Nurse practitioner care improves renal outcome in patients with CKD. Journal of the American Society of Nephrology : JASN, 2014, Volume: 25, Issue:2 Topics: Aged; Ambulatory Care Facilities; Antihypertensive Agents; Aspirin; Biomarkers; Cholesterol, LDL; Cr	2014
Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. BMJ open, 2014, Feb-25, Volume: 4, Issue:2 Topics: Acute Kidney Injury; Adrenergic alpha-2 Receptor Agonists; Anti-Inflammatory Agents, Non-Steroidal;	2014
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. Contemporary clinical trials, 2015, Volume: 43 Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co	2015
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC nephrology, 2015, Jun-27, Volume: 16 Topics: Arteriovenous Shunt, Surgical; Aspirin; Central Venous Catheters; Docosahexaenoic Acids; Double-Blin	2015
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology (Carlton, Vic.), 2016, Volume: 21, Issue:3 Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Australia; Comorbidity; Docosahexaenoic Acids;	2016
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. The American journal of cardiology, 2016, Feb-15, Volume: 117, Issue:4 Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up	2016
Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODI International journal of cardiology, 2016, Jun-01, Volume: 212 Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug T	2016
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke, 2016, Volume: 47, Issue:11 Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Comorbidity; Drug Therapy, Combi	2016
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:6 Topics: Aged; Aspirin; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Creatinine; Double-Blind Me	2012
Assessment of the Siksika chronic disease nephropathy-prevention clinic. Canadian family physician Medecin de famille canadien, 2013, Volume: 59, Issue:1 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bl	2013

Article	Year
The role of aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease. European journal of preventive cardiology, 2022, 02-03, Volume: 28, Issue:17 Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Renal Insufficiency, Chronic	2022
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. Stroke, 2022, Volume: 53, Issue:2 Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45	2022
The association of frailty with chronic kidney disease in older adults using the ASPirin in reducing events in the elderly cohort. Nephrology (Carlton, Vic.), 2023, Volume: 28, Issue:1 Topics: Aged; Albuminuria; Aspirin; Cross-Sectional Studies; Frailty; Glomerular Filtration Rate; Humans; Re	2023
Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease. Scientific reports, 2022, 10-22, Volume: 12, Issue:1 Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Middle Aged; Platelet	2022
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances. Kardiologia polska, 2022, Volume: 80, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combinatio	2022
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. American heart journal, 2023, Volume: 264 Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Renal Insufficien	2023
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2020, 10-01, Volume: 96, Issue:4 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Dual	2020
Aspirin for primary prevention of CVD in CKD: where do we stand? The British journal of general practice : the journal of the Royal College of General Practitioners, 2019, Volume: 69, Issue:689 Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Renal Insufficiency, Chronic; Secondar	2019
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA network open, 2020, 04-01, Volume: 3, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo	2020
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:9 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Fe	2020
[Is Concomitant Therapy with Acetaminophen and Low-dose Aspirin a Risk Factor for CKD Progression? A 6-Year Cohort Study]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2020, Volume: 140, Issue:7 Topics: Acetaminophen; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Biomarkers; Creatinine; Diabete	2020
Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial. Pharmacoepidemiology and drug safety, 2021, Volume: 30, Issue:1 Topics: Aspirin; Humans; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Rivaroxaban	2021
"To take or not to take an aspirin?" The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease. Kidney international, 2021, Volume: 99, Issue:2 Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Renal Insufficiency,	2021
Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease patients and low bodyweight: results from KNOW-CKD study. Scientific reports, 2021, 03-23, Volume: 11, Issue:1 Topics: Aspirin; Body Weight; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Kidney Function T	2021
Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study : This is the study for kidney and pregnancy... Journal of nephrology, 2021, Volume: 34, Issue:5 Topics: Aspirin; Female; Humans; Kidney; Platelet Aggregation Inhibitors; Pre-Eclampsia; Pregnancy; Pregnanc	2021
Timing of bleeding and thromboembolism associated with endoscopic submucosal dissection for gastric cancer in Japan. Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:10 Topics: Anticoagulants; Aspirin; Endoscopic Mucosal Resection; Fibrinolytic Agents; Gastric Mucosa; Humans;	2021
The risk of lower gastrointestinal bleeding in low-dose aspirin users. Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi	2017
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ (Clinical research ed.), 2018, 02-14, Volume: 360 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; England; Fe	2018
Role of antiplatelet therapy in the durability of hemodialysis access. Journal of nephrology, 2018, Volume: 31, Issue:4 Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Databases, Factual; Female; Hospital Mortality;	2018
Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? : Editorial to: "Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Di Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:3 Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Humans; Primary Prevention; Renal Insufficien	2018
Comparison of the effects of antithrombotic therapy on delayed bleeding after gastric endoscopic resection: a propensity score-matched case-control study. Gastrointestinal endoscopy, 2019, Volume: 89, Issue:2 Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Case-Control Studies; Deprescriptions; Endoscopic Muco	2019
Prevalence of high on-treatment platelet reactivity in patients with chronic kidney disease treated with acetylsalicylic acid for stroke prevention. Polish archives of internal medicine, 2018, 11-30, Volume: 128, Issue:11 Topics: Adult; Age Factors; Aspirin; Blood Platelets; Case-Control Studies; Female; Humans; Male; Middle Age	2018
[Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease]. Kardiologiia, 2019, Apr-13, Volume: 59, Issue:3S Topics: Aged; Aspirin; Gastrointestinal Diseases; Humans; Prospective Studies; Pulmonary Disease, Chronic Ob	2019
Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study. Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:9 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Cohort Studies; Da	2013
Aspirin resistance in patients with impaired renal functions. Kardiologia polska, 2014, Volume: 72, Issue:4 Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Middle Aged; P	2014
Incidence and related factors of upper gastrointestinal bleeding in a Chinese population of peripheral arterial disease during a six-year follow-up. International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; China; Comorbidity; Female; Fibrinoly	2014
Evidence for preoperative aspirin improving major outcomes in patients with chronic kidney disease undergoing cardiac surgery: a cohort study. Annals of surgery, 2015, Volume: 261, Issue:1 Topics: Acute Kidney Injury; Aspirin; Cardiac Surgical Procedures; Glomerular Filtration Rate; Hospital Mort	2015
Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease. PloS one, 2014, Volume: 9, Issue:8 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabete	2014
Analgesia dose prescribing and estimated glomerular filtration rate decline: a general practice database linkage cohort study. BMJ open, 2014, Aug-19, Volume: 4, Issue:8 Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir	2014
Effect of low-dose proton pump inhibitor on preventing upper gastrointestinal bleeding in chronic kidney disease patients receiving aspirin. Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Dialysis; Female; Follow-Up Studies; Gastrointestinal Hemor	2015
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. The Canadian journal of cardiology, 2014, Volume: 30, Issue:10 Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin	2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. The Canadian journal of cardiology, 2014, Volume: 30, Issue:10 Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin	2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. The Canadian journal of cardiology, 2014, Volume: 30, Issue:10 Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin	2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. The Canadian journal of cardiology, 2014, Volume: 30, Issue:10 Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin	2014
Risk factors for early and delayed post-operative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agents. BMC gastroenterology, 2014, Oct-03, Volume: 14 Topics: Adenocarcinoma; Aged; Aspirin; Dissection; Female; Fibrinolytic Agents; Gastric Mucosa; Gastroscopy;	2014
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Journal of the American College of Cardiology, 2014, Dec-16, Volume: 64, Issue:23 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Female; Follow-Up Studi	2014
Aspirin Has a Protective Effect Against Adverse Outcomes in Patients with Nonvariceal Upper Gastrointestinal Bleeding. Digestive diseases and sciences, 2015, Volume: 60, Issue:7 Topics: Adult; Aged; Aging; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Fibrinolytic Agents	2015
Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2016, Volume: 18, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hong Kong; Hospitaliz	2016
Antiplatelet effects of aspirin in chronic kidney disease patients. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:2 Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Cross-	2016
Heart-Healthy Nutrition Approach for Chronic Kidney Disease Patients. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2016, Volume: 26, Issue:1 Topics: Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Cholesterol;	2016
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy. Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:5 Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combinati	2016
Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 05-23, Volume: 5, Issue:5 Topics: Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Coho	2016
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. European journal of clinical pharmacology, 2016, Volume: 72, Issue:11 Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions	2016
Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study. Medicine, 2016, Volume: 95, Issue:36 Topics: Adult; Age Factors; Aged; Aspirin; Female; Hemostasis, Endoscopic; Hospital Costs; Humans; Intubatio	2016
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney international, 2017, Volume: 91, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co	2017
Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. European journal of internal medicine, 2017, Volume: 39 Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Hematinics; Hemorrhage;	2017
Stroke and bleeding in atrial fibrillation with chronic kidney disease. The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7 Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,	2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease. The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7 Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,	2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease. The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7 Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,	2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease. The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7 Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,	2012
Chronic aspirin and statin therapy in patients with impaired renal function and acute coronary syndromes: results from the IN-ACS Outcome Registry. European journal of preventive cardiology, 2014, Volume: 21, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therap	2014
Atrial fibrillation and chronic kidney disease. The New England journal of medicine, 2012, 11-29, Volume: 367, Issue:22 Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie	2012
Atrial fibrillation and chronic kidney disease. The New England journal of medicine, 2012, 11-29, Volume: 367, Issue:22 Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie	2012
Atrial fibrillation and chronic kidney disease. The New England journal of medicine, 2012, 11-29, Volume: 367, Issue:22 Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie	2012

aspirin and Renal Insufficiency, Chronic